TNF and type 1 diabetes mellitus: In a 24-week clinical study, anti-TNFα therapy in human T1D patients was seen to reduce levels of glycated hemoglobin A1C (HbA1c), a marker indicative of blood glucose values over a 3-month period, as well as increase C-peptide levels suggesting preservation of β cell function (142).